Cardio Diagnostics Unveils Molecular Tests to Catch 50% Undetected CHD Cases
CDIO•Cardio Diagnostics reports that 50% of coronary heart disease patients lack traditional risk factors and that conventional risk calculators detect only 39% of cases. The company has launched epigenetic and genetic molecular tests to improve early CHD detection beyond standard factors.
1. Detection Limitations in Coronary Heart Disease
Coronary heart disease is underdiagnosed as half of patients show no traditional risk factors and standard risk calculators achieve only 39% sensitivity, leaving many individuals vulnerable to preventable cardiac events.
2. CDIO's Epigenetic and Genetic Test Technology
Cardio Diagnostics' molecular assays analyze gene expression and regulatory biomarkers at the epigenetic and genetic level to identify CHD risk in patients who appear low-risk by conventional measures.
3. Potential Market Impact and Next Steps
These advanced tests target a diagnostic blind spot and could drive broader adoption of molecular risk assessment, positioning Cardio Diagnostics to expand its footprint in the coronary heart disease screening market.
